HCB-302

N/A

Report date: 2023/08/29 17:45:55

Base Information

Drug NameHCB-302

Drug Alias NameHCB-302HCB302

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionImmunomodulators

TargetsUpdating

Therapy Area/IndicationsNeuroendocrine TumorsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesTaiwan +[9]

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHanchorBio Inc

China Registration ClassN/A

Develop Information

Active CompaniesHanchorBio Inc

Inactive CompaniesIpsen

Active IndicationsNeoplasms

Inactive IndicationsNeuroendocrine Tumors

Other Information

ATC CodeN/A